1. Home
  2. AUDC vs ENGN Comparison

AUDC vs ENGN Comparison

Compare AUDC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AudioCodes Ltd.

AUDC

AudioCodes Ltd.

N/A

Current Price

$10.07

Market Cap

247.7M

Sector

Utilities

ML Signal

N/A

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

N/A

Current Price

$1.90

Market Cap

117.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AUDC
ENGN
Founded
1992
1999
Country
Israel
Canada
Employees
N/A
N/A
Industry
Telecommunications Equipment
Sector
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
247.7M
117.2M
IPO Year
2000
2023

Fundamental Metrics

Financial Performance
Metric
AUDC
ENGN
Price
$10.07
$1.90
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$12.50
$21.08
AVG Volume (30 Days)
84.7K
655.9K
Earning Date
05-05-2026
06-11-2026
Dividend Yield
4.54%
N/A
EPS Growth
N/A
56.85
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.24
N/A
Revenue Next Year
$2.18
N/A
P/E Ratio
$23.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.95
$1.40
52 Week High
$10.86
$12.25

Technical Indicators

Market Signals
Indicator
AUDC
ENGN
Relative Strength Index (RSI) 51.65 54.93
Support Level $8.82 $1.67
Resistance Level $10.31 $1.95
Average True Range (ATR) 0.31 0.07
MACD -0.02 0.01
Stochastic Oscillator 67.56 77.78

Price Performance

Historical Comparison
AUDC
ENGN

About AUDC AudioCodes Ltd.

AudioCodes Ltd provides voice communications solutions for enterprises, contact centers, and service providers, including voice infrastructure, cloud-based platforms, and Voice AI applications. Its AudioCodes Live Platform is a cloud-based service delivery platform that enables provisioning, management, and operation of voice and AI-based communication services, including PSTN connectivity and integration with platforms such as Microsoft Teams, Webex Calling, and Zoom Phone. The company's solutions are organized into three layers: voice infrastructure and devices, cloud-based platforms, and Voice AI applications for contact center and productivity use cases. It also offers management tools such as One Voice Operations Center (OVOC), Device Manager, and AudioCodes Routing Manager (ARM).

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: